Co-Authors
This is a "connection" page, showing publications co-authored by NAOTO T UENO and FUNDA MERIC-BERNSTAM.
Connection Strength
1.571
-
Somatic mutations, clinicopathologic characteristics, and survival in patients with untreated breast cancer with bone-only and non-bone sites of first metastasis. J Cancer. 2018; 9(19):3640-3646.
Score: 0.167
-
Survival Outcomes by TP53 Mutation Status in Metastatic Breast Cancer. JCO Precis Oncol. 2018; 2018.
Score: 0.163
-
Prior systemic treatment increased the incidence of somatic mutations in metastatic breast cancer. Eur J Cancer. 2018 01; 89:64-71.
Score: 0.159
-
Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer. Breast Cancer Res. 2017 Aug 15; 19(1):93.
Score: 0.155
-
Identification of frequent somatic mutations in inflammatory breast cancer. Breast Cancer Res Treat. 2017 Jun; 163(2):263-272.
Score: 0.150
-
Clinical outcomes based on multigene profiling in metastatic breast cancer patients. Oncotarget. 2016 Nov 22; 7(47):76362-76373.
Score: 0.148
-
Multigene clinical mutational profiling of breast carcinoma using next-generation sequencing. Am J Clin Pathol. 2015 Nov; 144(5):713-21.
Score: 0.137
-
Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype? Oncotarget. 2015 May 30; 6(15):12890-908.
Score: 0.133
-
Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials. J Clin Oncol. 2015 Sep 01; 33(25):2753-62.
Score: 0.133
-
Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 2013 Oct 01; 19(19):5533-40.
Score: 0.118
-
Clinically relevant inflammatory breast cancer patient-derived xenograft-derived ex vivo model for evaluation of tumor-specific therapies. PLoS One. 2018; 13(5):e0195932.
Score: 0.041
-
Challenges and perspective of drug repurposing strategies in early phase clinical trials. Oncoscience. 2015; 2(6):576-80.
Score: 0.034
-
Functional consequence of the MET-T1010I polymorphism in breast cancer. Oncotarget. 2015 Feb 20; 6(5):2604-14.
Score: 0.033